ATE548374T1 - 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren - Google Patents

2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren

Info

Publication number
ATE548374T1
ATE548374T1 AT08840633T AT08840633T ATE548374T1 AT E548374 T1 ATE548374 T1 AT E548374T1 AT 08840633 T AT08840633 T AT 08840633T AT 08840633 T AT08840633 T AT 08840633T AT E548374 T1 ATE548374 T1 AT E548374T1
Authority
AT
Austria
Prior art keywords
indeaminase
desoxytetrahydrouridine
cytide
inhibitors
fluorine
Prior art date
Application number
AT08840633T
Other languages
English (en)
Inventor
Gregory Hamilton
Takashi Tsukamoto
Dana Ferraris
Bridget Duvall
Rena Lapidus
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE548374(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc filed Critical Eisai Inc
Application granted granted Critical
Publication of ATE548374T1 publication Critical patent/ATE548374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08840633T 2007-10-16 2008-10-16 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren ATE548374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (1)

Publication Number Publication Date
ATE548374T1 true ATE548374T1 (de) 2012-03-15

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08840633T ATE548374T1 (de) 2007-10-16 2008-10-16 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren

Country Status (39)

Country Link
US (4) US8268800B2 (de)
EP (2) EP2447272B1 (de)
JP (2) JP5496899B2 (de)
KR (1) KR101543049B1 (de)
CN (1) CN101827856B (de)
AT (1) ATE548374T1 (de)
BR (1) BRPI0818672B8 (de)
CA (1) CA2702274C (de)
CO (1) CO6270330A2 (de)
CR (1) CR11427A (de)
CY (3) CY1112781T1 (de)
DK (1) DK2207786T3 (de)
EA (1) EA018757B1 (de)
EC (1) ECSP10010095A (de)
ES (2) ES2616566T3 (de)
FI (2) FIC20230039I1 (de)
FR (2) FR23C1052I2 (de)
GT (1) GT201000088A (de)
HR (1) HRP20120419T1 (de)
HU (2) HUS2300045I1 (de)
IL (1) IL204732A (de)
JO (1) JO2778B1 (de)
LT (2) LTPA2023539I1 (de)
ME (1) ME00997B (de)
MX (1) MX2010004109A (de)
MY (1) MY147970A (de)
NI (1) NI201000055A (de)
NL (2) NL301257I2 (de)
NO (2) NO2023048I1 (de)
NZ (1) NZ584229A (de)
PL (1) PL2207786T3 (de)
PT (1) PT2207786E (de)
RS (1) RS52323B (de)
SA (1) SA08290661B1 (de)
SI (1) SI2207786T1 (de)
TW (1) TWI445539B (de)
UA (1) UA99476C2 (de)
WO (1) WO2009052287A1 (de)
ZA (1) ZA201002178B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
AU2009246926B2 (en) 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
US8716263B2 (en) * 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8329666B2 (en) * 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
CA2757745C (en) * 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
ES2593088T3 (es) * 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
US8609631B2 (en) * 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EP2646453A1 (de) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Verbindungen
SMT201800087T1 (it) 2011-09-16 2018-03-08 Gilead Pharmasset Llc Metodi per trattare hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
KR102272773B1 (ko) 2013-10-29 2021-07-02 오츠카 세이야쿠 가부시키가이샤 2'-데옥시-2',2'-디플루오로테트라하이드로우리딘의 합성 경로
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3925609B1 (de) 2014-08-22 2025-07-30 Celgene Corporation Verfahren zur behandlung von multiplem myelom mit immunmodulatorischen verbindungen in kombination mit antikörpern
DK3960182T3 (da) 2015-12-03 2025-04-07 Epidestiny Inc Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin samt anvendelser deraf
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3746134A1 (de) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Kleinmolekülige wirkstoffkonjugate von gemcitabinmonophosphat
EP3844477A4 (de) * 2018-08-28 2023-01-04 Essenlix Corporation Verbesserung der assay-genauigkeit
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
EP3868774A4 (de) * 2018-10-19 2023-05-10 Interoligo Corporation Modifizierte nukleinsäure mit verbesserter behandlungseffizienz und pharmazeutische antikrebszusammensetzung damit
JP7433662B2 (ja) * 2018-10-19 2024-02-20 インターオリゴ・コーポレイション 治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物
PH12022550795A1 (en) * 2019-10-08 2023-09-25 Otsuka Pharma Co Ltd 2`-deoxy-2`,2`-difluorotetrahydrouridines with high purity and methods of making the same
BR112022013264A2 (pt) * 2020-02-25 2022-11-16 Otsuka Pharma Co Ltd Combinação de formas de dosagem oral sólida de decitabina e cedazuridina
IL307181A (en) * 2021-03-26 2023-11-01 Cleveland Clinic Found Treatment of RNA virus infection with a cytidine deaminase inhibitor
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20250127806A1 (en) * 2021-11-01 2025-04-24 St. John's University Injectable liquid pharmaceutical composition containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
CA3266274A1 (en) 2022-08-31 2024-03-07 Taiho Pharmaceutical Co., Ltd. Combination therapies for the treatment of T-cell lymphoma with tolinapant, cedazuridine, and decitabin

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0160079B1 (de) 1983-10-26 1990-01-31 GREER, Sheldon B. Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CA2086233C (en) 1991-04-23 1995-10-17 Wendy Oglevee-O'donovan In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
DE69403588T2 (de) 1993-02-23 1998-01-22 Hope City 4-ethoxy-5-fluor-2'-deoxyuridine
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
AU5300396A (en) * 1995-03-01 1996-09-18 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
WO2000051639A2 (en) * 1999-03-01 2000-09-08 Halogenetics, Inc. Treatment of neoplastic diseases by radiation
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
NZ517437A (en) 1999-08-26 2004-02-27 Omega Critical Care Ltd Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN100368422C (zh) 2000-11-29 2008-02-13 三井化学株式会社 L-核酸衍生物及其合成方法
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
AU2002322805B2 (en) * 2001-07-31 2007-11-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
WO2003068162A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
AU2003291726A1 (en) 2002-11-04 2004-06-07 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
EP1812457A1 (de) 2004-07-30 2007-08-01 Pharmaessentia Corp. Stereoselektive synthese von b-nukleosiden
MX2007006837A (es) 2004-12-08 2007-10-23 Sicor Inc Difluoronucleosidos y proceso de preparacion de los mismos.
WO2008085611A2 (en) 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
US8329666B2 (en) 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
CA2757745C (en) 2009-04-06 2018-02-13 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2593088T3 (es) 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer

Also Published As

Publication number Publication date
AU2008312435A8 (en) 2014-07-24
TW200924786A (en) 2009-06-16
ES2616566T3 (es) 2017-06-13
DK2207786T3 (da) 2012-06-18
FIC20230039I1 (fi) 2023-12-22
ZA201002178B (en) 2011-05-25
BRPI0818672B8 (pt) 2021-05-25
WO2009052287A1 (en) 2009-04-23
UA99476C2 (en) 2012-08-27
EP2207786A1 (de) 2010-07-21
AU2008312435A1 (en) 2009-04-23
NL301256I2 (nl) 2024-01-11
CY1112781T1 (el) 2016-02-10
IL204732A (en) 2013-07-31
PT2207786E (pt) 2012-05-28
HRP20120419T1 (hr) 2012-07-31
GT201000088A (es) 2012-03-13
FR23C1052I2 (fr) 2025-02-07
EP2207786B1 (de) 2012-03-07
CR11427A (es) 2010-08-16
NI201000055A (es) 2010-08-13
US20150210730A1 (en) 2015-07-30
SI2207786T1 (sl) 2012-10-30
US9567363B2 (en) 2017-02-14
HUS2300044I1 (hu) 2024-01-28
CY2023028I1 (el) 2024-02-16
US8268800B2 (en) 2012-09-18
NL301256I1 (de) 2024-01-03
HUS2300045I1 (hu) 2024-01-28
MY147970A (en) 2013-02-28
CY2023029I1 (el) 2024-02-16
ME00997B (me) 2012-10-20
KR101543049B1 (ko) 2015-08-07
CA2702274C (en) 2015-12-29
EA201000642A1 (ru) 2010-10-29
FIC20230040I1 (fi) 2023-12-22
FR23C1052I1 (fr) 2024-01-26
CA2702274A1 (en) 2009-04-23
US20090137521A1 (en) 2009-05-28
BRPI0818672A2 (pt) 2015-04-14
SA08290661B1 (ar) 2012-06-10
FR23C1051I1 (fr) 2024-01-26
NO2023047I1 (no) 2023-12-21
US8951987B2 (en) 2015-02-10
NZ584229A (en) 2012-06-29
BRPI0818672B1 (pt) 2020-10-20
CN101827856B (zh) 2013-02-06
LTPA2023539I1 (de) 2024-02-26
LTPA2023538I1 (de) 2024-02-26
ECSP10010095A (es) 2010-07-30
EP2447272A1 (de) 2012-05-02
US8618075B2 (en) 2013-12-31
ES2384011T3 (es) 2012-06-28
MX2010004109A (es) 2010-08-10
EA018757B1 (ru) 2013-10-30
JP5496899B2 (ja) 2014-05-21
FR23C1051I2 (fr) 2025-02-07
JO2778B1 (en) 2014-03-15
EP2447272B1 (de) 2017-02-01
KR20100091978A (ko) 2010-08-19
NL301257I2 (nl) 2025-11-06
CN101827856A (zh) 2010-09-08
US20140186335A1 (en) 2014-07-03
LTC2207786I2 (de) 2025-09-10
PL2207786T3 (pl) 2012-09-28
RS52323B (sr) 2012-12-31
TWI445539B (zh) 2014-07-21
US20120289475A1 (en) 2012-11-15
CO6270330A2 (es) 2011-04-20
JP2011500713A (ja) 2011-01-06
AU2008312435B2 (en) 2014-04-17
IL204732A0 (en) 2010-11-30
HK1146410A1 (en) 2011-06-03
JP2014177455A (ja) 2014-09-25
NO2023048I1 (en) 2023-12-21
JP5859588B2 (ja) 2016-02-10

Similar Documents

Publication Publication Date Title
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
ECSP10010722A (es) Compuestos orgánicos
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
CY1112402T1 (el) Ενισχυτες υποδοχεων γλουταμικου
EA200970156A1 (ru) Пиридизиноновые производные
NO20084334L (no) Farmasoytiske sammensetninger
DK1776011T3 (da) Fungicid sammensætning, indeholdende et syreamidderivat
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
PA8792401A1 (es) Fenilendiaminas
PA8667201A1 (es) Nuevos compuestos farmaceuticos
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
EA201000069A1 (ru) Новые гербициды
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
ATE430148T1 (de) Neue pyrrolodihydroisochinoline als pde10- inhibitoren
BRPI0516602A (pt) composto, e, composição farmacêutica
NO20063293L (no) Farmasoytiske forbindelser
TW200716130A (en) Purified form of tanaproget